

27 November 2019

The Manager
Company Announcements Office
ASX Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By: e-lodgement


Dear Sir/Madam

RESULTS OF ANNUAL GENERAL MEETING

Cynata Therapeutics Limited (ASX: CYP) advises that its Annual General Meeting of Shareholders was held today at 11.00 am (AEDT).

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours faithfully



Peter Webse
Company Secretary

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

Annual General Meeting

Wednesday, 27 November 2019



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
01 Adoption of Remuneration Report	P	43,522,975	36,744,894	6,249,006	702,872	529,075	37,913,133	6,643,508	1,002,872
02 Re-election of Mr Peter Webse as a Director	P	50,019,847	44,737,570	4,267,328	294,144	1,014,949	46,392,011	4,982,277	294,144
03 Re-election of Dr Paul Wotton as a Director	P	49,661,004	41,578,972	7,118,517	652,987	963,515	43,233,413	7,782,032	652,987
04 Re-election of Dr Geoffrey Brooke as a Director	P	49,729,847	45,595,346	3,119,552	584,144	1,014,949	47,249,787	3,834,501	584,144
05 Renewal of Employee Option Acquisition Plan	P	47,469,265	31,337,937	15,168,163	316,226	963,165	32,992,378	15,831,328	316,226
06 Approval of 10% Placement Facility	P	49,576,867	43,017,441	5,593,522	737,124	965,904	44,671,882	6,259,426	737,124
07 Requisitioned Resolution to amend Company's Constitution - The board unanimously recommends that Shareholders vote AGAINST Resolution 7	P	50,066,198	10,250,833	39,260,590	247,793	554,775	10,671,035	40,749,604	247,793

